Theravance Biopharma, Inc. (TBPH) - Stock Analysis
Last updated: Apr 26, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Theravance Biopharma benefits from record sales growth, upcoming Phase 3 CYPRESS data expected Q1 2026 as a key catalyst, positive technical momentum (+27% last month), and strong sector tailwinds, supporting near-term upside despite ongoing losses and high valuation.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Weak Operations ⢠Mixed Cash Flow TBPH looks financially solid on liquidity, leverage, and valuation, but recent quarterly losses and weak core operating performance temper the otherwise attractive setup.
Price Behavior
Key Price Behavior Insights: ⢠Support holding ⢠Resistance test ⢠Momentum cooling Support Level: $16.0-$16.1 Resistance Level: $17.2-$17.3 TBPH has shown a mildly bullish uptrend over the last month, holding key support near $16.0-$16.1 but still needing a break above $17.2-$17.3 to confirm renewed upside.
Sentiment & News
Key News Insights: ⢠Trial failure fallout ⢠Legal scrutiny rising ⢠Shares under pressure Theravance Biopharma has faced a wave of investor investigations and legal scrutiny in April 2026 after its CYPRESS Phase 3 trial failure and weak guidance concerns pressured shares, even as some institutional buying and momentum commentary offered limited support.
AI Summary
TBPH should now be viewed less as a pipeline re-rating story and more as a balance-sheet-backed commercial cash-flow turnaround, where the key investment question is whether YUPELRI growth plus a 60% cost reset can replace the lost CYPRESS upside and produce durable free cash flow before the market permanently assigns a lower multiple.
Description
Theravance Biopharma is a biopharmaceutical company that researches, develops and commercializes respiratory medicines across the United States, Europe and Asia, with YUPELRI sold as a nebulized, once-daily therapy for COPD. Its clinical pipeline includes inhaled and gut-targeted small moleculesânotably several JAK inhibitors and other candidates addressing pulmonary and gastrointestinal disordersâalongside later-stage programs for autonomic and motility conditions. The company maintains licensing and collaboration agreements with major pharmaceutical partners and is incorporated in 2013 with headquarters in George Town, Cayman Islands.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 5 | Dec 12 | TBPH | Theravance Biopharma, Inc. | Theravance Biopharma benefits from record sales growth, upcoming Phase 3 CYPRESS data expected Q1 2026 as a key catalyst, positive technical momentum (+27% last month), and strong sector tailwinds, supporting near-term upside despite ongoing losses and high valuation. | Closed | -2.1% |